Heart failure (HF) is a common and serious
comorbidity of diabetes. Oxidative stress has
been associated with the pathogenesis of
chronic diabetic complications including cardiomyopathy.
The ability of antioxidants to
inhibit injury has raised the possibility of new
therapeutic treatment for diabetic heart diseases.
Riboflavin constitutes an essential
nutrient for humans and animals and it is an
important food additive. Riboflavin, a precursor
of flavin mononucleotide (FMN) and flavin
adenine dinucleotide (FAD), enhances the
oxidative folding and subsequent secretion of
proteins. The objective of this study was to
investigate the cardioprotective effect of
riboflavin in diabetic rats. Diabetes was
induced in 30 rats by a single injection of
streptozotocin (STZ) (70 mg /kg). Riboflavin
(20 mg/kg) was orally administered to animals
immediately after induction of diabetes and
was continued for eight weeks. Rats were
examined for diabetic cardiomyopathy by left
ventricular (LV) remadynamic function.
Myocardial oxidative stress was assessed by measuring the activity of superoxide dismutase (SOD), the level of malondialdehyde (MDA) as well as heme oxygenase-1 (HO-1) protein level. Myocardial connective tissue growth factor (CTGF) level was measured by Western blot in all rats at the end of the study. In the untreated diabetic rats, left ventricular systolic pressure (LVSP) rate of pressure rose (+dp/dt), and rate of pressure decay (−dp/dt) were depressed while left ventricular enddiastolic pressure (LVEDP) was increased, which indicated the reduced left ventricular contractility and slowing of left ventricular relaxation. The level of SOD decreased, CTGF and HO-1 protein expression and MDA content rose. Riboflavin treatment significantly improved left ventricular systolic and diastolic function in diabetic rats, there were persistent increases in significant activation of SOD and the level of HO-1 protein, and a decrease in the level of CTGF. These results suggest that riboflavin treatment ameliorates myocardial function and improves heart oxidant status, whereas raising myocardial HO-1 and decreasing myocardial CTGF levels have beneficial effects on diabetic cardiomyopathy.
Riboflavin, diabetic cardiomyopathy, heme oxygenase-1.
Guoguang Wang, Department of Pathophysiology, Wannan Medical College, Wuhu 241000, China. E-mail: email@example.com.
Share this Article
Related Content In Heart Failure
49/Multi-disciplinary heart failure- Device clinic improves management of heart failure patients following complex device implantatio
European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr49
Introduction: Complex device therapy (CDT) [cardiac resynchronisation therapy pacemaker or defibrillator (CRTP or CRTD) and implantable cardioverter defibrillator (ICD)], is recommended in patients with heart failure (HF) with severe left ventricular systolic dysfunction if they are still symptomatic despite optimisation HF medication. Several patients however, will only tolerate optimal doses of these drugs after CDT, […]
47/Association between very high NT-proBNP levels, and haemoglobin and ferritin
European Journal of Arrhythmia & Electrophysiology. 2021;7(Suppl. 1):abstr47
Introduction: The adverse prognosis in heart failure (HF) correlates with both NT-proBNP and high-sensitivity CRP levels. The latter indicates a greater underlying inflammatory process in more severe heart failure. This inflammatory response is also evidenced by elevated ferritin (acute phase reactant) and reduced haemoglobin (bone marrow suppression) amongst these patients. It is unclear if there […]
Management of Atrial Fibrillation in Recipients of Cardiac Resynchronization Therapy
European Journal of Arrhythmia & Electrophysiology. 2021;7(1):19-25 DOI: https://doi.org/10.17925/EJAE.2021.7.1.19
Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity of HF symptoms, from about 5% of patients in the New York Heart Association (NYHA) class I to 50% in NYHA class IV.1–4 Consistently, the incidence of AF […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!